Clinical impact of the analytical specificity of the hybrid capture 2 test: Data from the new technologies for cervical cancer (NTCC) study

Journal of Clinical Microbiology

Volumn 51, Issue 9, 2013, Pages 2901-2907

  Gillio Tos, Anna ^a   De Marco, Laura ^a   Carozzi, Francesca Maria ^b   Del Mistro, Annarosa ^c   Girlando, Salvatore ^d   Burroni, Elena ^b   Frayle Salamanca, Helena ^c   Rossi, Paolo Giorgi ^e   Pierotti, Paola ^f   Ronco, Guglielmo ^g  

^a UNIVERSITY OF TURIN   (Italy)

^b ISPO Cancer Prevention and Research Institute   (Italy)

^c VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

^d SANTA CHIARA HOSPITAL   (Italy)

^e PATHOLOGY UNIT   (Italy)

^f MAGGIORE HOSPITAL   (Italy)

^g Centre for Cancer Prevention   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ANALYTIC METHOD; ARTICLE; CONTROLLED STUDY; CROSS REACTION; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST; DIAGNOSTIC VALUE; DNA DETERMINATION; DNA SEQUENCE; FALSE POSITIVE RESULT; FEMALE; GENOTYPE; HUMAN; HYBRID CAPTURE TEST; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; PAPILLOMAVIRUS INFECTION; PREDICTIVE VALUE; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SENSITIVITY AND SPECIFICITY; TRANSPORT MEDIUM; VIRUS LOAD; WOMEN'S HEALTH;

ADULT; FEMALE; HUMANS; MOLECULAR DIAGNOSTIC TECHNIQUES; NUCLEIC ACID HYBRIDIZATION; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PREDICTIVE VALUE OF TESTS; SENSITIVITY AND SPECIFICITY; UTERINE CERVICAL NEOPLASMS; YOUNG ADULT;

EID: 84882791739     PISSN: 00951137     EISSN: 1098660X     Source Type: Journal    
DOI: 10.1128/JCM.01047-13     Document Type: Article

References (37)

1. Cuzick J, Mayrand MH, Ronco G, Snijders P, Wardle J. 2006. Chapter 10: new dimensions in cervical cancer screening. Vaccine 24(Suppl 3): S3/90-S3/97.
2. Ronco G, Segnan N, Giorgi-Rossi P, Zappa M, Casadei G, Crozzi F, Dalla Palma P, Del Mistro A, Focalidi S, Gillio-Tos A, Nardo G, Naldoni C, Schincaglia P, Zorzi M, Confortini M, Cuzick J, and the Working Group NTCC. 2006. Human papillomavirus testing and liquidbased cytology in primary cervical screening: results at recruitment from NTCC randomized controlled trial. J. Natl. Cancer Inst. 98:765-774. doi: 10.1093/jnci/djj209.
3. Mayrand MH, Duarte-Franco E, Rodrigues I, Walter SD, Hanley J, Ferenczy A, Ratnam S, Coutlée F, Franco EL; Canadian Cervical Cancer Screening Trial Study Group. 2007. Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer. N. Engl. J. Med. 357: 1579-1588.
4. Ronco G, Giorgi-Rossi P, Carozzi F, Confortini M, Dalla Palma P, Del Mistro A, Gillio-Tos A, Minucci D, Naldoni C, Rizzolo R, Schincaglia P, Volante R, Zappa M, Zorzi M, Cuzick J, Segnan N; New Technologies for Cervical Cancer Screening Working Group. 2008. Results at recruitment from a randomized controlled trial comparing human papillomavirus testing alone with conventional cytology as the primary cervical cancer screening test. J. Natl. Cancer Inst. 100:492-501.
5. Leinonen M, Nieminen P, Kotaniemi-Talonen L, Malila N, Tarkkanen J, Laurila P, Anttila A. 2009. Age-specific evaluation of primary human papillomavirus screening vs conventional cytology in a randomized setting. J. Natl. Cancer Inst. 101:1612-1623.
6. Kitchener HC, Almonte M, Thomson C, Wheeler P, Sargent A, Stoykova B, Gilham C, Baysson H, Roberts C, Dowie R, Desai M, Mather J, Bailey A, Turner A, Moss S, Peto J. 2009. HPV Testing in Combination with Liquid-based Cytology in Primary Cervical Screening (ARTISTIC): A Randomised Controlled Trial. Lancet Oncol. 10:672-682.
7. Meijer CJ, Berkhof J, Castle PE, Hesselink AT, Franco EL, Ronco G, Arbyn M, Bosch FX, Cuzick J, Dillner J, Heideman DA, Snijders PJ. 2009. Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and older. Int. J. Cancer 124:516-520.
8. Giorgi-Rossi P, Franceschi S, Ronco G. 2012. HPV prevalence and accuracy of HPV testing to detect high-grade cervical intraepithelial neoplasia. Int. J. Cancer 130:1387-1394.
9. Bouvard V, Baan R, Straif K, El Ghissassi F, Benbrahim-Tallaa L, Guha N, Freeman C, Galichet L, Gogliano V, on behalf of the WHO IARC in Cancer Monograph Working Group. 2009. A review of human carcinogens. Part B: biological agents. Lancet Oncol. 10:321-322.
10. Lindemann ML, Dominguez MJ, de Antonio JC, Sandri MT, Tricca A, Sideri M, Khiri H, Ravet S, Boyle S, Aldrich C, Halfon P. 2012. Analytical comparison of the cobas HPV test with Hybrid Capture 2 for the detection of high-risk HPV genotypes. J. Mol. Diagn. 14:65-70.
11. Castle PE, Solomon D, Wheeler CM, Gravitt PE, Wacholder S, Shiffman M. 2008. Human papillomavirus genotype specificity of Hybrid Capture. J. Clin. Microbiol. 46:2595-2604.
12. Safaeian M, Herrero R, Hildesheim A, Quint W, Freer E, Van Doorn LJ, Porras C, Silva S, González P, Bratti MC, Rodriguez AC, Castle P, Costa Rican Vaccine Trial Group. 2007. Comparison of the SPF10-LiPA system to the Hybrid Capture 2 Assay for detection of carcinogenic human pap-illomavirus genotypes among 5,683 young women in Guanacaste, Costa Rica. J. Clin. Microbiol. 45:1447-1454.
13. Schiffman M, Wheeler CM, Dasgupta A, Solomon D, Castle PE, ALTS Group. 2005. A comparison of a prototype PCR assay and hybrid capture 2 for detection of carcinogenic human papillomavirus DNA in women with equivocal or mildly abnormal papanicolaou smears. Am. J. Clin. Pathol. 124:722-732.
14. Poljak M, Marin IJ, Seme K, Vince A. 2002. Hybrid Capture II HPV test detects at least 15 human papillomavirus genotypes not included in its current high-risk probe cocktail. J. Clin. Virol. 25(Suppl 3):S89-S97. doi: 10.1016/S1386-6532(02)00187-7.
15. Castle PE, Schiffman M, Burk RD, Wacholder S, Hildesheim A, Herrero R, Bratti MC, Sherman ME, Lorincz A. 2002. Restricted crossreactivity of hybrid capture 2 with nononcogenic human papillomavirus types. Cancer Epidemiol. Biomarkers Prev. 11:1394-1399.
16. Schneede P, Hillemanns P, Ziller F, Hofstetter A, Stockfleth E, Arndt R, Meyer T. 2001. Evaluation of HPV testing by Hybrid Capture II for routine gynecologic screening. Acta Obstet. Gynecol. Scand. 80:750-752.
17. Terry G, Ho L, Londesborough P, Cuzick J, Mielzynska-Lohnas I, Lorincz A. 2001. Detection of high-risk HPV types by the hybrid capture 2 test. J. Med. Virol. 65:155-162.
18. Yamazaki H, Sasagawa T, Basha W, Segawa T, Inoue M. 2001. Hybrid capture-II and LCR-E7 PCR assays for HPV typing in cervical cytologic samples. Int. J. Cancer 94:222-227.
19. Peyton CL, Schiffman M, Lörincz AT, Hunt WC, Mielzynska I, Bratti C, Eaton S, Hildesheim A, Morera LA, Rodriguez AC, Herrero R, Sherman ME, Wheeler CM. 1998. Comparison of PCR-and hybrid capture-based human papillomavirus detection systems using multiple cervical specimen collection strategies. J. Clin. Microbiol. 36:3248-3254.
20. Sargent A, Bailey A, Almonte M, Turner A, Thomson C, Peto J, Desai M, Mather J, Moss S, Roberts C, Kitchener HC, ARTISTIC Study Group. 2008. Prevalence of type-specific HPV infection by age and grade of cervical cytology: data from the ARTISTIC trial. Br. J. Cancer 98:1704-1709.
21. Dalstein V, Merlin S, Bali C, Saunier M, Dachez R, Ronsin C. 2008. Analytical evaluation of the PapilloCheck test, a new commercial DNA chip for detection and genotyping of human papillomavirus J. Virol. Methods 156:77-83.
22. Seme K, Fujs K, Kocjan BJ, Poljak M. 2006. Resolving repeatedly borderline results of Hybrid Capture 2HPVDNAtest using polymerase chain reaction and genotyping. J. Virol. Methods 134:252-256.
23. Carozzi FM, Del Mistro A, Confortini M, Sani C, Puliti D, Trevisan R, De Marco L, Gillio-Tos A, Girlando S, Dalla Palma P, Pellegrini A, Schiboni ML, Crucitti P, Pierotti P, Vignato A, Ronco G. 2005. Reproducibility of HPV DNA testing by Hybrid Capture 2 in a screening setting. Am. J. Clin. Pathol. 124:716-721.
24. Ronco G, Giorgi-Rossi P, Carozzi F, Confortini M, Dalla Palma P, Del Mistro A, Ghiringhello B, Girlando S, Gillio-Tos A, De Marco L, Naldoni C, Pierotti P, Rizzolo R, Schincaglia P, Zorzi M, Zappa M, Segnan N, Cuzick J, New Technologies for Cervical Cancer screening (NTCC) Working Group. 2010. Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial. Lancet Oncol. 11:249-257.
25. Dong SM, Pai SI, Rha SH, Hildesheim A, Kurman RJ, Schwartz PE, Mortel R, McGowan L, Greenberg MD, Barnes WA, Sidransky D. 2002. Detection and quantitation of human papillomavirus DNA in the plasma of patients with cervical carcinoma. Cancer Epidemiol. Biomarkers. Prev. 11:3-6.
26. Carozzi F, Tornesello ML, Burroni E, Loquercio G, Carillo G, Angeloni C, Scalisi A, Macis R, Chini F, Buonaguro FM, Giorgi Rossi P, HPV Prevalence Italian Working Group. 2010. Prevalence of human papillomavirus types in high-grade cervical intraepithelial neoplasia and cancer in Italy. Cancer Epidemiol. Biomarkers Prev. 19:2389-2400.
27. Geraets DT, Heideman DA, de Koning MN, Snijders PJ, Meijer CJ, van Doorn LJ, Quint WG. 2009. High genotyping concordance between the DigeneHPVgenotypingRHtest and the reverse line blot genotyping assay on GP5+/6+-PCR products. J. Clin. Virol. 46(Suppl 3):S16-S20. doi:10 .1016/S1386-6532(09)70296-3.
28. van den Brule AJ, Pol R, Fransen-Daalmeijer N, Schouls LM, Meijer CJ, Snijders PJ. 2002. GP5+/6+ PCR followed by reverse line blot analysis enables rapid and high-throughput identification of human papillomavirus genotypes. J. Clin. Microbiol. 40:779-787.
29. Eklund C, Forslund O, Wallin KL, Zhou T, Dillner J, WHO Human Papillomavirus Laboratory Network. 2012. The 2010 global proficiency study of human papillomavirus genotyping in vaccinology. J. Clin. Microbiol. 50:2289-2298.
30. Nobre RJ, de Almeida LP, Martins TC. 2008. Complete genotyping of mucosal human papillomavirus using a restriction fragment length polymorphism analysis and an original typing algorithm. J. Clin. Virol. 42:13-21.
31. Dalla Palma P, Giorgi-Rossi P, Collina G, Buccoliero AM, Ghiringhello B, Lestani M, Onnis GL, Aldovini D, Galanti G, Casadei GP, Aldi M, Gomes V, Giubilato V, Ronco G, NTCC Pathology Group. 2008. The risk of false-positive histology according to the reason for colposcopy referral in cervical cancer screening: a blind revision of all histological lesions found in the NTCC trial. Am. J. Clin. Pathol. 129:75-80.
32. Arbyn M, Ronco G, Cuzick J, Wentzensen N, Castle PE. 2009. How to evaluate emerging technologies in cervical screening? Int. J. Cancer 125: 2489-2496.
33. Castle PE, Cox JT, Jeronimo J, Solomon D, Wheeler CM, Gravitt PE, Schiffman M. 2008. An analysis of high-risk human papillomavirus DNAnegative cervical precancers in the ASCUS-LSIL Triage Study (ALTS). Obstet. Gynecol. 111:847-856.
34. Schiffman M, Herrero R, Desalle R, Hildesheim A, Wacholder S, Rodriguez AC, Bratti MC, Sherman ME, Morales J, Guillen D, Alfaro M, Hutchinson M, Wright TC, Solomon D, Chen Z, Schussler J, Castle PE, Burk RD. 2005. The carcinogenicity of human papillomavirus types reflects viral evolution. Virology 337:76-84.
35. Menzo S, Ciavattini A, Bagnarelli P, Marinelli K, Sisti S, Clementi M. 2008. Molecular Epidemiology and Pathogenic Potential of Underdiagnosed Human Papillomavirus Types. BMC Microbiol. 8:112. doi:10.1186/1471-2180-8-112.
36. Schmitt M, Dondog B, Waterboer T, Pawlita M, Tommasino M, Gheit T. 2010. Abundance of multiple high-risk human papillomavirus (HPV) infections found in cervical cells analyzed by use of an ultrasensitive HPV genotyping assay. J. Clin. Microbiol. 48:143-149.
37. Rebolj M, Bonde J, Njor SH, Lynge E. 2011. Human papillomavirus testing in primary cervical screening and the cut-off level for hybrid capture 2 tests: systematic review. BMJ 342:d2757. doi:10.1136/bmj.d2757.